Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Xencor, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05032040CT.gov A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vudalimab (this asset) | Xencor, Inc. | P2 | CC · 42 |
| Indocyanine Green | Istanbul University | P4 | BB |
| Adriamycin | AstraZeneca | P3 | BB |
| Olaparib | Qilu Pharmaceutical Co., Ltd. | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Nivestim | Mayo Clinic | P3 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P3 | B |
| Patent Blue Violet | Centre Oscar Lambret | P3 | B |
+42 more in the Endometrial Carcinoma cohort
Other indications for Vudalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Clear Cell Adenocarcinoma | — | P2 | CC · 43 |
| Cervical Carcinoma | — | P2 | CC · 43 |
| Castration-Resistant Prostate Carcinoma | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vudalimab in Endometrial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vudalimab-endometrial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →